ResMed (RMD) Tops Q4 EPS by 3c, Revenue Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Morgan Stanley Upgrades ResMed (RMD) to Overweight
July 31, 2015 10:01 AM EDTMorgan Stanley upgraded ResMed (NYSE: RMD) from Equalweight to Overweight.
For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.
Shares of ResMed closed at $56.12 yesterday.
... MoreResMed (RMD) PT Bumped to $66 at Needham & Company Posts Q4
July 31, 2015 8:02 AM EDTNeedham & Company analyst Mike Matson reiterated a Buy rating and raised his price target on ResMed (NYSE: RMD) to $66.00 (from $65.00) following solid Q4 results driven by flow generator product cycle.
Matson commented, "RMD's revenue and EPS beat consensus as its revenue... More
Deutsche Bank Downgrades ResMed (RMD) to Sell
July 31, 2015 7:32 AM EDTDeutsche Bank downgraded ResMed (NYSE: RMD) from Hold to Sell with a price target of $53.00 (from $61.00). The change follows Q4 results. Analyst David Low noted strong sales offset by GM weakness.
"After the incredible success of ResMeds AirSense range we are wary FY16... More
